Safety Profile
Known Safety Concerns
- UL 20 mg per day -- exceeded in high-dose sports supplements
- Influences estrogen and testosterone metabolism -- relevant in hormone-sensitive conditions
- Boric acid forms are toxic at high doses (industrial/pesticide concentrations)
- Limited long-term safety data at supplemental doses
Contraindications
- UL 20 mg per day -- exceeded in high-dose sports supplements
- Influences estrogen and testosterone metabolism -- relevant in hormone-sensitive conditions
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Boron is a trace mineral with roles in bone health, hormone metabolism, and cognitive function. It influences estrogen and testosterone metabolism. Evidence for benefits is emerging but not conclusive. The UL is 20 mg per day. Boric acid at high doses is toxic — historically used as an antiseptic and insecticide. Most consumer supplements contain 3-10 mg per serving which is well within the safe range.
Biological and Chemical Classification
- Scientific Name
- Boron (as boron citrate / boron glycinate / boric acid)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- UL 20 mg per day -- exceeded in high-dose sports supplements
- Influences estrogen and testosterone metabolism -- relevant in hormone-sensitive conditions
- Boric acid forms are toxic at high doses (industrial/pesticide concentrations)
- Limited long-term safety data at supplemental doses
The available scientific evidence for Boron indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 24 მარ 2026, 08:36
Evidence Distribution
-
Observational / other LOW evidence YELLOWDual Photothermal and Magnetothermal Responsive Shape Memory Polyurethane with Magnetic Navigation Capability. ↗Xue Z et al.. Dual Photothermal and Magnetothermal Responsive Shape Memory Polyurethane with Magnetic Navigation Capability.. ACS Appl Mater Interfaces. 2026. PMID:41872044.PMID 41872044 ↗Journal ACS Appl Mater InterfacesYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41872044/
-
Observational / other LOW evidence YELLOWConvergent evolution increases boron transport through SNPs and tandem duplications at BOR1 and BOR2 in Arabidopsis thaliana. ↗Tergemina E et al.. Convergent evolution increases boron transport through SNPs and tandem duplications at BOR1 and BOR2 in Arabidopsis thaliana.. Proc Natl Acad Sci U S A. 2026. PMID:41871252.PMID 41871252 ↗Journal Proc Natl Acad Sci U S AYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41871252/
-
Observational / other LOW evidence YELLOWSynthesis and Properties of Boron Fluoride Complexes Using 2-(N-Pyridylamino)-1-azaazulene derivatives. ↗Morimoto H et al.. Synthesis and Properties of Boron Fluoride Complexes Using 2-(N-Pyridylamino)-1-azaazulene derivatives.. J Org Chem. 2026. PMID:41869687.PMID 41869687 ↗Journal J Org ChemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41869687/
-
Observational / other LOW evidence YELLOWControllable Synthesis and VLS Growth Mechanism of Boron Nitride Nanotubes Catalyzed by Lithium Carbonate. ↗Huang Y et al.. Controllable Synthesis and VLS Growth Mechanism of Boron Nitride Nanotubes Catalyzed by Lithium Carbonate.. ACS Omega. 2026. PMID:41867517.PMID 41867517 ↗Journal ACS OmegaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41867517/
-
Observational / other LOW evidence YELLOWRh(II)-Catalyzed Enantioselective B-H Insertion of Cyclic Alkyl-Donor Carbene Generated from Diynes. ↗Liu S et al.. Rh(II)-Catalyzed Enantioselective B-H Insertion of Cyclic Alkyl-Donor Carbene Generated from Diynes.. Org Lett. 2026. PMID:41866716.PMID 41866716 ↗Journal Org LettYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41866716/
-
Observational / other LOW evidence YELLOWArchitecting optimized thermal conduction pathways in colonnade-structured polydimethylsiloxane-based thermal interface materials by direct ink writing. ↗Ruan K et al.. Architecting optimized thermal conduction pathways in colonnade-structured polydimethylsiloxane-based thermal interface materials by direct ink writing.. Sci Bull (Beijing). 2026. PMID:41864785.PMID 41864785 ↗Journal Sci Bull (Beijing)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41864785/
-
Observational / other LOW evidence YELLOWOperando ATR-FTIR elucidation of surface-mediated photocatalytic pathways on metal-free nanomaterials. ↗Mohamed HH et al.. Operando ATR-FTIR elucidation of surface-mediated photocatalytic pathways on metal-free nanomaterials.. Spectrochim Acta A Mol Biomol Spectrosc. 2026. PMID:41864001.PMID 41864001 ↗Journal Spectrochim Acta A Mol Biomol SpectroscYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41864001/
-
Observational / other LOW evidence YELLOWDepth-of-interaction enhanced Compton camera using pixelated LYSO(Ce) scintillator arrays and dual-ended SiPMs. ↗Tian X et al.. Depth-of-interaction enhanced Compton camera using pixelated LYSO(Ce) scintillator arrays and dual-ended SiPMs.. Appl Radiat Isot. 2026. PMID:41861488.PMID 41861488 ↗Journal Appl Radiat IsotYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41861488/
-
Observational / other LOW evidence YELLOWMolecular Dynamics of Heteroatom-Doped Graphene Electrodes and Hybrid Electrolytes for High-Performance Ionic Liquid Supercapacitors. ↗Wang M et al.. Molecular Dynamics of Heteroatom-Doped Graphene Electrodes and Hybrid Electrolytes for High-Performance Ionic Liquid Supercapacitors.. Chemphyschem. 2026. PMID:41861118.PMID 41861118 ↗Journal ChemphyschemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41861118/
-
Observational / other LOW evidence YELLOWCarbonless amino acids and a carbonless GHK peptide. ↗Skurski P et al.. Carbonless amino acids and a carbonless GHK peptide.. Phys Chem Chem Phys. 2026. PMID:41859865.PMID 41859865 ↗Journal Phys Chem Chem PhysYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41859865/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Boron. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Boron
A score of 3.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.